Company: CDLX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001666071-25-000159
Chunk: 99

Company: Cardlytics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 99
---
601 Accumulated deficit(1,395,814)(1,300,576)Total stockholders’ (deficit) equity(4,704)69,993 Total liabilities and stockholders’ equity$292,807 $392,711 

See notes to the condensed consolidated financial statements3

Table of Contents

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands, except per share amounts)

 Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2025202420252024Revenue$52,031 $67,057 $177,178 $204,301 Costs and expenses:Partner Share and other third-party costs22,001 30,675 78,554 94,476 Delivery costs5,730 7,830 19,901 21,664 Sales and marketing expense7,865 13,163 31,954 41,306 Research and development expense8,799 13,194 31,800 39,712 General and administrative expense10,854 12,076 37,537 42,712 Acquisition, integration and divestiture costs— — — 162 Change in contingent consideration— 100 102 110 Impairment of goodwill and intangible assets58,843 131,595 58,843 131,595 Loss (gain) on disposal or divestiture320 — (4,831)— Depreciation and amortization expense6,473 6,970 19,039 19,749 Total costs and expenses120,885 215,603 272,899 391,486 Operating Loss(68,854)(148,546)(95,721)(187,185)Other (expense) income:Interest expense, net(2,007)(1,479)(5,780)(3,859)Foreign currency (loss) gain(1,812)4,843 6,263 4,312 Gain on debt extinguishment— — — 13,017 Total other (expense) income(3,819)3,364 483 13,470 Loss before income taxes(72,673)(145,182)(95,238)(173,715)Net Loss$(72,673)$(145,182)$(95,238)